Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion

被引:73
作者
Chevreau, C
Mazerolles, C
Soulié, M
Gaspard, MH
Mourey, L
Bujan, L
Plante, P
Rischmann, P
Bachaud, JM
Malavaud, B
机构
[1] CHU Rangueil, Dept Urol, F-31403 Toulouse, France
[2] CHU Rangueil, Dept Pathol, F-31403 Toulouse, France
[3] Inst Claudius Regaud, Dept Med Oncol, F-31052 Toulouse, France
[4] CHU Toulouse Paule Viguier, Dept Reprod Med, CECOS, Toulouse, France
关键词
stage INSGCT; adjuvant chemotherapy; BEP; fertility;
D O I
10.1016/j.eururo.2004.03.022
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To report the long-term impact of two cycles of adjuvant chemotherapy on relapse rates and treatment-related morbidity in high-risk stage I nonseminomatous testicular germ cell tumors (NSGCTT 1). Material and Methods: From April 1987 to September 1997, 40 stage I NSGCTT patients with evidence of vascular invasion and/or embryonal carcinoma (EC) in the orchidectomy specimen were treated with two courses of bleomycin, cisplatin, and etoposide (BEP). Results: All patients but one (incidental death) were alive after an extended follow-up (median 113.2 months, range 63-189). No patients relapsed but two patients presented a second cancer in the remaining testis. Short-term toxicity was minimal and no long-term toxicity was observed. Conclusion: The present series, with extensive follow-up, demonstrated that the efficacy and toxicity of two cycles of BEP compared well with the results of surveillance strategies or RPLND in high-risk stage I NSGCTT. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 50 条
[1]   Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial [J].
Albers, P ;
Siener, R ;
Kliesch, S ;
Weissbach, L ;
Krege, S ;
Sparwasser, C ;
Schulze, H ;
Heidenreich, A ;
de Riese, W ;
Loy, V ;
Bierhoff, E ;
Wittekind, C ;
Fimmers, R ;
Hartmann, M .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1505-1512
[2]  
Ansquer Y, 2001, CANCER, V91, P2329, DOI 10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO
[3]  
2-U
[4]  
BANIEL J, 1994, WORLD J UROL, V12, P139
[5]   Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indiana University experience [J].
Behnia, M ;
Foster, R ;
Einhorn, LH ;
Donohue, J ;
Nichols, CR .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (04) :472-475
[6]   Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors [J].
Böhlen, D ;
Borner, M ;
Sonntag, RW ;
Fey, MF ;
Studer, UE .
JOURNAL OF UROLOGY, 1999, 161 (04) :1148-1152
[7]   RISK OF SECONDARY LEUKEMIA FOLLOWING HIGH CUMULATIVE DOSES OF ETOPOSIDE DURING CHEMOTHERAPY FOR TESTICULAR CANCER [J].
BOKEMEYER, C ;
SCHMOLL, HJ ;
KUCZYK, MA ;
BEYER, J ;
SIEGERT, W .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (01) :58-60
[8]   Long-term complications of chemotherapy for germ cell tumours [J].
Chaudhary, UB ;
Haldas, JR .
DRUGS, 2003, 63 (15) :1565-1577
[9]   Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A medical research council report [J].
Cullen, MH ;
Stenning, SP ;
Parkinson, MC ;
Fossa, SD ;
Kaye, SB ;
Horwich, AH ;
Harland, SJ ;
Williams, MV ;
Jakes, R .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1106-1113
[10]   PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION IN CLINICAL STAGE A NONSEMINOMATOUS GERM-CELL TESTIS CANCER - REVIEW OF THE INDIANA-UNIVERSITY EXPERIENCE 1965-1989 [J].
DONOHUE, JP ;
THORNHILL, JA ;
FOSTER, RS ;
ROWLAND, RG ;
BIHRLE, R .
BRITISH JOURNAL OF UROLOGY, 1993, 71 (03) :326-335